Search
News & Events
Meningococcal research paves way for vaccine useA series of The Kids Research Institute Australia studies looking at safety for Meningococcal ACWY vaccines in children has led the way for its use in Australia.
News & Events
Community Conversation- Infectious Diseases in ChildrenConsumers and community members are invited to join us to provide input into our childhood infectious diseases research.
News & Events
Vaccination timing essentialWe all know how important it is to vaccinate a child against harmful diseases but vaccinating a child at the right wrong age can cost lives.
News & Events
Experts gather for Aboriginal Immunisation WorkshopExperts in Aboriginal infectious disease research are in Perth this week for the National Indigenous Immunisation Research Workshop (November 7-8).
News & Events
New vaccine could protect against more types of cancer-causing HPVTrial of new vaccine that could provide women with additional protection against Human Papillomavirus (HPV) types known to cause cervical cancer.
News & Events
Perth women needed for international cervical cancer studyPerth women are being invited to take part in a global study of an exciting new vaccine that could protect against cervical cancer
Research
Th2-polarisation of cellular immune memory to neonatal pertussis vaccinationCurrent infant vaccination against pertussis in North America and Australia requires three doses of vaccines including diphtheria, tetanus and acellular...
Research
Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic studySince 1955, the recommended strategy for rheumatic heart disease secondary prophylaxis has been benzathine penicillin G injections administered intramuscularly every 4 weeks. Due to dosing frequency, pain, and programmatic challenges, adherence is suboptimal. It has previously been demonstrated that BPG delivered subcutaneously at a standard dose is safe and tolerable and has favorable pharmacokinetics, setting the scene for improved regimens with less frequent administration.
Research
Estimating measures to reduce the transmission of SARS-CoV-2 in Australia to guide a ‘National Plan’ to reopeningThe availability of COVID-19 vaccines promised a reduction in the severity of disease and relief from the strict public health and social measures (PHSMs) imposed in many countries to limit spread and burden of COVID-19. We were asked to define vaccine coverage thresholds for Australia's transition to easing restrictions and reopening international borders.